Cargando…

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

BACKGROUND: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-2′-deoxycytodine (decitabine) can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glasspool, R M, Brown, R, Gore, M E, Rustin, G J S, McNeish, I A, Wilson, R H, Pledge, S, Paul, J, Mackean, M, Hall, G D, Gabra, H, Halford, S E R, Walker, J, Appleton, K, Ullah, R, Kaye, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992493/ https://www.ncbi.nlm.nih.gov/pubmed/24642620 http://dx.doi.org/10.1038/bjc.2014.116

Ejemplares similares

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
por: Samani, A., et al.
Publicado: (2022)

Response to the letter entitled “Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers”
por: Samani, A., et al.
Publicado: (2022)

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.
por: Rankin, E. M., et al.
Publicado: (1992)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)
por: Momparler, Richard L.
Publicado: (2013)

A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
por: Momparler, Richard L.
Publicado: (2012)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

How nephrotoxic is carboplatin?
por: Hardy, J. R., et al.
Publicado: (1990)

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
por: Perren, T. J., et al.
Publicado: (1993)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers
por: Cartwright, D., et al.
Publicado: (2022)

Carboplatin and renal function in children.
por: Stevens, M. C., et al.
Publicado: (1991)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
por: Karahoca, Metin, et al.
Publicado: (2013)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Dose-related nephrotoxicity of carboplatin in children
por: English, M W, et al.
Publicado: (1999)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study
por: Benson, Eric A., et al.
Publicado: (2015)

Effects of Treatment with the Hypomethylating Agent 5-aza-2′-deoxycytidine in Murine Type II Collagen-Induced Arthritis
por: Petralia, Maria Cristina, et al.
Publicado: (2019)

The Effect of 5-aza,2’-deoxyCytidine (5 AZA CdR or Decitabine) on Extrinsic, Intrinsic, and JAK/STAT Pathways in Neuroblastoma and Glioblastoma Cells Lines
por: Sanaei, Masumeh, et al.
Publicado: (2023)

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
por: Momparler, Richard L, et al.
Publicado: (2014)

5-Aza-2′-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts
por: Alpoim-Moreira, Joana, et al.
Publicado: (2023)

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia.
por: Richel, D. J., et al.
Publicado: (1991)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.
por: Rustin, G. J., et al.
Publicado: (1988)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Identification of a class of human cancer germline genes with transcriptional silencing refractory to the hypomethylating drug 5-aza-2′-deoxycytidine.
por: Almatrafi, Ahmed, et al.
Publicado: (2014)

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases
por: Jansen, Yanina J L, et al.
Publicado: (2019)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma
por: Strauss, S J, et al.
Publicado: (2003)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
por: Budden, Timothy, et al.
Publicado: (2018)

Five-aza-2′-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells
por: Tsujioka, Takayuki, et al.
Publicado: (2015)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Targeted anti-vascular therapies for ovarian cancer: current evidence
por: Hall, M, et al.
Publicado: (2013)

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
por: Peng, B., et al.
Publicado: (1997)

Inhibition of DNA and Histone Methylation by 5-Aza-2′-Deoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells
por: Momparler, Richard L., et al.
Publicado: (2017)

A pilot study of carboplatin (JM8, CBDCA) and chlorambucil in combination for advanced ovarian cancer.
por: Harding, M., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_mks6illqero33vcpfr55kicapo